Top

Published in:

01-08-2007 | Original

High-mobility group box 1 protein plasma concentrations during septic shock

Authors: Sébastien Gibot, Frédéric Massin, Aurélie Cravoisy, Damien Barraud, Lionel Nace, Brune Levy, Pierre-Edouard Bollaert

Published in: Intensive Care Medicine | Issue 8/2007

Abstract

Objective

To investigate plasma high-mobility group box 1 protein (HMGB1) concentration and its relationship with organ dysfunction and outcome in septic shock patients.

Design and setting

Prospective, noninterventional study. Medical adult intensive care unit at a university hospital in France.

Patients

42 critically ill patients with septic shock.

Methods

Arterial blood was drawn within 12 h of admission for the measurement of plasma HMGB1 concentration by ELISA. Repeated sampling was performed on days 3, 7, and 14.

Results

Median HMGB1 concentration was 4.4 ng/ml (IQR 1.2–12.5) at admission, with no difference between survivors and nonsurvivors. A positive correlation was observed between HMGB1 and SOFA score and lactate, and procalcitonin concentrations. There was a progressive but statistically nonsignificant decline in HMGB1 concentration among the survivors, while nonsurvivors showed an increase in HMGB1 level between days 1 and 3. SOFA score and lactate and procalcitonin concentrations did not vary significantly between days 1 and 3. When measured on day 3, HMGB1 discriminated survivors from nonsurvivors with 66% sensitivity and 67% specificity, and concentration greater than 4 ng/ml was associated with an odds ratio of death of 5.5 (95% CI 1.3–23.6).

Bustin M, Hopkins RB, Isenberg I (1978) Immunological relatedness of high mobility group chromosomal proteins from calf thymus. J Biol Chem 253:1694–1699PubMed

West KL, Castellini MA, Duncan MK, Bustin M (2004) Chromosomal proteins HMGN3a and HMGN3b regulate the expression of glycine transporter 1. Mol Cell Biol 24:3747–3756PubMedCrossRef

Park JS, Arcaroli J, Yum HK, Yang H, Wang KY, Choe KH, Strassheim D, Pitts TM, Tracey KF, Abraham E (2003) Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284:C870–C879PubMed

Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251PubMedCrossRef

Sansonetti PJ (2006) The innate signalling of dangers and the dangers of innate signalling. Nat Immunol 7:1237–1242PubMedCrossRef

Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, Ilyinskaia O, Tararak E, Bobik A (2004) Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions. Role of activated macrophages and cytokines. Atheroscler Thromb Vasc Biol 24:2320–2325CrossRef

Chen G, Li J, Ochani M, Rendon-Mitchell B, Qiang X, Susarla S, Ulloa L, Yang H, Fan S, Goyert SM, Wang P, Tracey KJ, Sama AE, Wang H (2004) Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol 76:994–1001PubMedCrossRef

Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191–195PubMedCrossRef

Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5:825–830PubMedCrossRef

10.

Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, ovitechi D (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem 270:25752–25761PubMedCrossRef

11.

Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E (2004) Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279:7370–7377PubMedCrossRef

12.

Ombrellino M, Wang H, Ajemian MS, Talhouk A, Scher LA, Friedman SG, Tracey KJ (1999) Increased serum concentrations of high-mobility-group protein 1 in hemorrhagic shock. Lancet 354:1446–1447PubMedCrossRef

13.

Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48:971–981PubMedCrossRef

14.

Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ (2004) Reversing established sepsis with antagonists of endogenous HMGB1. Proc Natl Acad Sci USA 101:296–301PubMedCrossRef

15.

Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 99:12351–12356PubMedCrossRef

16.

Chen G, Li J, Qiang X, Czura CJ, Ochani M, Ochani K, Ulloa L, Yang H, Tracey KJ, Wang P, Sama AE, Wang H (2005) Suppression of HMGB-1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 46:623–627PubMedCrossRef

17.

Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33:564–573PubMedCrossRef

18.

Janeway CA Jr (1989) Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54:1–13PubMed

19.

Medzhitov R, Janeway CA Jr (1997) Innate immunity: the virtues of a nonclonal system of recognition. Cell 91:295–298PubMedCrossRef

20.

Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085–2088PubMedCrossRef

21.

Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301–305PubMedCrossRef

22.

Krzeslak A, Lipinska A (2004) Galectin-3 as a multifunctional protein. Cell Miol Biol Lett 9:305–328

23.

Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monach DM, Dixit VM (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228–232PubMedCrossRef

24.

Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516–521PubMedCrossRef

25.

Yamada S, Maruyami I (2007) HMGB1, a novel inflammatory cytokine. Clin Chim Acta 375:36–42PubMedCrossRef

26.

Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE (2007) Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 81:67–74PubMedCrossRef

27.

Yamada S, Inoue K, Yakabe K, Imaizumi H, Maruyama I (2003) High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem 49:1535–1537PubMedCrossRef

28.

Yamada S, Yakabe K, Ishii J, Imaizumi H, Maruyama I (2006) New high mobility group box 1 assay system. Clin Chim Acta 372:173–178PubMedCrossRef

29.

Gaini S, Pedersen SS, Pedersen C, Koldkjaer OG, Moller HJ (2007) High mobility group box-1 protein (HMGB1) in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care 11:R32PubMedCrossRef

30.

Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, Uemoto S, Yamada S, Maruyama I (2005) Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 94:975–979PubMed

31.

Eriksson M (2005) Should high mobility group box-1 protein (HMGB1) be measured in patients with severe sepsis and septic shock? If so, when, where, and how? Crit Care Med 33:682–683PubMedCrossRef

Title: High-mobility group box 1 protein plasma concentrations during septic shock
Authors: Sébastien Gibot
Frédéric Massin
Aurélie Cravoisy
Damien Barraud
Lionel Nace
Brune Levy
Pierre-Edouard Bollaert
Publication date: 01-08-2007
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 8/2007
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-007-0691-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

High-mobility group box 1 protein plasma concentrations during septic shock

Abstract

Objective

Design and setting

Patients

Methods

Results

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Design and setting

Patients

Methods

Results

Please log in to get access to this content

Other articles of this Issue 8/2007

Management of ventilator-associated pneumonia in a multidisciplinary intensive care unit: does trauma make a difference?

Reply to Moser and Röggla

Urinary biomarker of oxidative stress correlating with outcome in critically septic patients

Microdialysis of the rectus abdominis muscle for early detection of impending abdominal compartment syndrome

Understanding high-frequency oscillation: lessons from the animal kingdom

A postural change test improves the prediction of a radiological maxillary sinusitis by ultrasonography in mechanically ventilated patients